Galleri test by Grail

Multi-cancer early detection screening from a blood test

Multi-cancer early detection (MCED) testing is a new approach to screening for cancer. While recommended single-cancer screenings play an important role in detecting five specific cancers today – breast, cervical, colorectal, lung (smokers considered at risk) and prostate cancers – nearly 70% of deaths are caused by cancers without recommended screening.*1 Adding a blood-based multi-cancer early detection test can help screen for many of the deadliest cancers that don’t have recommended screening today.

Benefits of multi-cancer early detection screening

Treating cancer starts with knowing you have it. Most cancers show no symptoms until later stages, when treatment options may be limited. The public health goal of commercializing an MCED test is to increase cancer detection rates without increasing the burden on healthcare systems. To do this, GRAIL developed a test with high (>99%) specificity that is able to predict the origin of the cancer while minimizing testing-associated potential risks, including overdiagnosis.

*Assumes screening is available for all prostate, breast, cervical, and colorectal cancer cases and 43% of lung cancer cases (based on the estimated proportion of lung cancers that occur in screen-eligible individuals older than 40 years).